Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody

Triple-negative breast cancer (TNBC) is an aggressive disease with poor prognosis and limited therapeutic options. Recent advances in the immunotherapy field have enabled the development of new treatment strategies, among which the use of bispecific antibodies (BsAbs), able to redirect T cells again...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Silvia Martini, Mariangela Figini, Aurora Croce, Barbara Frigerio, Marzia Pennati, Alessandro Massimo Gianni, Cinzia De Marco, Maria Grazia Daidone, Christian Argueta, Yosef Landesman, Nadia Zaffaroni, Alessandro Satta
Materialtyp: Artigo
Språk:Inglês
Publicerad: MDPI AG 2020-10-01
Serie:Cells
Ämnen:
TRAIL-R2
bispecific antibody
selinexor
survivin
T cells
Länkar:https://www.mdpi.com/2073-4409/9/10/2231
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk